1. Home
  2. IPW vs RLYB Comparison

IPW vs RLYB Comparison

Compare IPW & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPW
  • RLYB
  • Stock Information
  • Founded
  • IPW 2018
  • RLYB 2018
  • Country
  • IPW United States
  • RLYB United States
  • Employees
  • IPW N/A
  • RLYB N/A
  • Industry
  • IPW Catalog/Specialty Distribution
  • RLYB Biotechnology: Pharmaceutical Preparations
  • Sector
  • IPW Consumer Discretionary
  • RLYB Health Care
  • Exchange
  • IPW Nasdaq
  • RLYB Nasdaq
  • Market Cap
  • IPW 19.8M
  • RLYB 24.1M
  • IPO Year
  • IPW 2021
  • RLYB 2021
  • Fundamental
  • Price
  • IPW $0.54
  • RLYB $0.59
  • Analyst Decision
  • IPW
  • RLYB Hold
  • Analyst Count
  • IPW 0
  • RLYB 2
  • Target Price
  • IPW N/A
  • RLYB N/A
  • AVG Volume (30 Days)
  • IPW 341.0K
  • RLYB 316.7K
  • Earning Date
  • IPW 11-13-2025
  • RLYB 11-06-2025
  • Dividend Yield
  • IPW N/A
  • RLYB N/A
  • EPS Growth
  • IPW N/A
  • RLYB N/A
  • EPS
  • IPW N/A
  • RLYB N/A
  • Revenue
  • IPW $74,105,251.00
  • RLYB $761,000.00
  • Revenue This Year
  • IPW $8.31
  • RLYB N/A
  • Revenue Next Year
  • IPW $77.15
  • RLYB N/A
  • P/E Ratio
  • IPW N/A
  • RLYB N/A
  • Revenue Growth
  • IPW N/A
  • RLYB 154.51
  • 52 Week Low
  • IPW $0.41
  • RLYB $0.22
  • 52 Week High
  • IPW $2.36
  • RLYB $1.24
  • Technical
  • Relative Strength Index (RSI)
  • IPW 47.20
  • RLYB 54.34
  • Support Level
  • IPW $0.49
  • RLYB $0.57
  • Resistance Level
  • IPW $0.63
  • RLYB $0.62
  • Average True Range (ATR)
  • IPW 0.05
  • RLYB 0.04
  • MACD
  • IPW 0.01
  • RLYB -0.00
  • Stochastic Oscillator
  • IPW 47.12
  • RLYB 73.71

About IPW iPower Inc.

iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Share on Social Networks: